ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Wang, Yu; Wang, Xiaohua; Yu, Yixin; Yuan, Liyan; Yu, Xiaoling; Yang, Bin*南方医科大学
Dermatologic Therapy2021-9DOI: 10.1111/dth.15081
4被引11阅读
引用收藏
分享

摘要

Secukinumab, a full human immunoglobulin G1 kappa monoclonal antibody that targets interleukin-17A, has demonstrated remarkable efficacy and appreciable tolerance in patients with moderate-to-severe psoriasis. However, data on its real-life performance, particularly on drug survival in China are limited. To investigate the efficacy, safety, and drug survival of secukinumab in Chinese patients with psoriasis, we conducted a monocentric retrospective study of 66 patients with moderate-to-severe psoriasis to followed-up for 52 weeks. At week 12, 86.4%, 57.6%, and 10.6% of the patients attained 75% improvement in psoriasis area and severity Index (PASI) score from baseline (PASI 75), PASI 90, and PASI 100 responses, respectively. The quality of life of patients markedly improved. The overall survival rate was 74.2%. Adverse events occurred in 30 patients (45.5%). The results revealed favorable efficacy, safety, and tolerability of secukinumab in the treatment of patients with psoriasis and provided data on drug survival in real-life clinical setting in China for the first time.

学科与关键词

关键词
drug survivalefficacypsoriasissafetysecukinumab
相关
加载中…
  • Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study
    Ding, Yangfeng; Li, Wei; Guan, Xin; Liu, Na; Zhou, Ying; Li, Gaojie; Wang, Xiaohua; Wang, Zhidong; Xiao, Xiao; Yang, Bin*; Lv, Chengzhi*; Zhang, Chunlei*; Shi, Yuling*CTS-Clinical and Translational Science, 2023, 16(10): 1803-1814.被引 1
  • Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Chinese Medical Journal, 2020, 133(22): 2665-2673.
  • Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
    Ying, Li; Suyun, Ji; Yanhua, Liang; Yunsheng, Liang; Li, Deng; Lin, Dang; Chengzhi, Lv; Bingjiang, Lin; Furen, Zhang; Wendi, Shi; Jinnan, Li; Yu, Dong; Guanshen, Dou; Shi, Yuling*ADVANCES IN THERAPY, 2023, 40(12): 5464-5474.
查看全部 →

发表信息

论文状态
公开发表
期刊
Dermatologic Therapy
发表日期
2021-09
卷期
第 34 卷, 第 5 期
页码
e15081
DOI
10.1111/dth.15081
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81903200]

作者

  • W

    Wang, Yu (第一作者)

    southern med univ

  • W

    Wang, Xiaohua

    southern med univ

查看全部 6 位作者收起作者
  • Y

    Yu, Yixin

    southern med univ

  • Y

    Yuan, Liyan

    southern med univ

  • Y

    Yu, Xiaoling

    southern med univ

  • Y

    Yang, Bin (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417